Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director
06 Febrero 2019 - 3:01PM
|
Press
Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
|
Sanofi's Board of Directors notes the resignation of Christian
Mulliez and co-opts Christophe Babule as Director
- Notes the resignation of Christian Mulliez as of February 6,
2019
- Co-opts Christophe Babule for the remainder of Christian
Mulliez's term of office
PARIS - February 6, 2019 - At its meeting
held on February 6, 2019, the Board of Directors duly noted the
resignation of Mr. Mulliez and decided, after consultation of the
Appointments and Governance Committee, to co-opt Christophe Babule
as Director for the remainder of Christian Mulliez's term of office
(expiring at the end of the Annual Shareholders' Meeting held in
2022 to approve the financial statements for the fiscal year ending
December 31, 2021).
The co-optation of Christophe Babule will be
subject to ratification by the next Shareholders' Meeting of
Sanofi, on April 30, 2019.
On November 19, 2018 Christophe Babule has been
appointed Executive Vice-President, Chief Financial Officer and
member of L'Oréal's Executive Committee as of mid-February 2019.
Christophe Babule has spent his career with L'Oréal, which he
joined in 1988 after his studies at HEC Paris. He spent 7 years in
the Luxury Division in Italy before being appointed as Director of
Administration & Finance based in China. In 2007, he was
appointed Administration & Financial Director for Mexico. In
2010, he returned to France to join Christian Mulliez's Executive
Committee as Director of Internal Audit for nearly 5 years.
Afterwards he was appointed to his current position as
Administration & Financial Director for the Asia Pacific Zone
based in Shanghai and then in Hong Kong.
In making this appointment, the Board of
Directors has chosen an individual with recognized skills in
high-priority areas for the Group while maintaining the current
balance of competences, in accordance with the roadmap set by the
Board relative to its composition.
The entire Board of Directors thanked Christian
Mulliez, who was also member of the Audit Committee and the
Compensation Committee, for his very substantial and active
participation in the meetings of the Board and of its
Committees.
The Board of Directors has 16 members, including
11 who are deemed independent and two Directors representing
employees.
About Sanofi Sanofi is dedicated to supporting
people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe. Sanofi, Empowering Life |
Media Relations ContactQuentin Vivant Tel.: +33 (0)1 53 77
41 09Quentin.Vivant@sanofi.com |
Investor Relations
ContactGeorge GrofikTel.: +33 (0)1 53 77 45
45ir@sanofi.com |
|
About Sanofi
Sanofi is dedicated to supporting people through
their health challenges. We are a global biopharmaceutical company
focused on human health. We prevent illness with vaccines, provide
innovative treatments to fight pain and ease suffering. We stand by
the few who suffer from rare
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024